アデプタス・ヘルス

 ADPTのチャート


 ADPTの企業情報

symbol ADPT
会社名 Adeptus Health Inc (アデプタス・ヘルス)
分野(sector)   
産業(industry)   
業種    医療関連(Health Care)
概要 ―  アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所「ファ―スト・チョイス・エマ―ジェンシ―・ル―プ」を所有、運営する。  Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
本社所在地 2941 Lake Vista Drive Lewisville TX 75067 USA
代表者氏名
代表者役職名
電話番号
設立年月日 41699
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3202人
url www.adhc.com
nasdaq_url
adr_tso
EBITDA
終値(lastsale)
時価総額(marketcap)
時価総額
売上高
企業価値(EV)
当期純利益
決算概要
symbol ADPT
会社名 Adeptus Health Inc (アダプティブ・バイオテクノロジーズ(Adaptive Biotechnologies Corp))
分野(sector)   
産業(industry)   
業種 バイオテクノロジー & メディカル リサーチ   医療関連 (Health Care)
概要 ―  アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所「ファ―スト・チョイス・エマ―ジェンシ―・ル―プ」を所有、運営する。  Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
本社所在地 2941 Lake Vista Drive Lewisville TX 75067 USA
代表者氏名 Chad M. Robins
代表者役職名 Executive Chairman Chief Executive Officer Co-Founder
電話番号 +1 206-659-0067
設立年月日 41699
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3202人
url www.adhc.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) -70.60000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 4567.03600
売上高 売上高(百万ドル) 85.07100
企業価値(EV) 企業価値(EV)(百万ドル) 4026.77700
当期純利益 当期純利益(百万ドル) -69.57000
決算概要 BRIEF: For the fiscal year ended 31 December 2019 Adaptive Biotechnologies Corp revenues increased 53% to $85.1M. Net loss applicable to common stockholders increased 50% to $69.6M. Revenues reflect Development revenue increase of 83% to $41.6M Sequencing revenue increase of 32% to $43.5M. Higher net loss reflects Research and development - Balancing increase of 84% to $66.8M (expense).

 ADPTのテクニカル分析


 ADPTのニュース

   Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020  2020/07/09 12:05:00 GlobeNewswire
SEATTLE, July 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to…
   Antibody drugs to prevent and treat the coronavirus are storming into the clinic. Here are the 8 top drugmakers crafting these treatments, which could be ready this fall.  2020/06/11 14:44:00 Business Insider
An antibody therapeutic could land in the sweet spot of the hunt for a coronavirus treatment. Several drug candidates have just started human testing or are planning to enter the clinic the next few weeks. If successful, they could be available this fall, far sooner than a vaccine. They are likely to work much better against the virus than drugs being tested now in patients, since they are designed to fight the novel coronavirus. There are five major ongoing research efforts for an antibody treatment. The leading programs run by Eli Lilly and Regeneron started clinical trials in June. Other drugmakers in the hunt include Vir Biotechnology, GlaxoSmithKline, Amgen, Adaptive Biotechnologies, AbbVie, and AstraZeneca. Visit Business Insider's homepage for more stories . In the sprint for an effective coronavirus treatment, several of the biggest drugmakers in the world have all landed on the same strategy. Companies like Regeneron and Eli Lilly want to use the body's own disease-fighting proteins, called antibodies, as the source material to develop coronavirus drugs.
   Microsoft and a $5 billion Seattle biotech just unveiled a massive database that reveals 'blind spots' in coronavirus research, and it could help us make better COVID-19 tests and vaccines (ADPT, MSFT)  2020/06/11 13:05:00 Business Insider
Microsoft and the Seattle biotech Adaptive Biotechnologies have found "blind spots" on the coronavirus that could be good targets for vaccines. The tech duo has been studying the virus and the human body's immune response to it for the past two months. On Thursday, they made their massive dataset freely available to all researchers. Microsoft and Adaptive are also now working on developing a new kind of diagnostic test to complement antibody testing. Their work is focused on T-cells, the body's first line of defense against viruses. "We didn't have the tools to study the T-cell response well in humans. It's sort of been left behind," Adaptive Chief Scientific Officer Harlan Robins told Business Insider. "Now we have those tools." For more stories like this, sign up here for our healthcare newsletter Dispensed . Coronavirus researchers may be zoomed too far in on one specific element of the virus. Several months into the outbreak, many scientists chasing a coronavirus vaccine are focused on one particular element of the virus, the spike protein.
   Here's how 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic  2020/06/08 16:57:00 Business Insider
Leading drugmakers are researching treatments and vaccines for the novel coronavirus. The small biotech Moderna has leaped to the front of the race, with a vaccine candidate that's already had some results. Pharma giants like Johnson & Johnson, Sanofi, Pfizer, and Merck have also jumped into the vaccine race. There's no assurance the vaccines will work. A vaccine might be available for emergency use by the fall, but likely won't be available widely until 2021 at the earliest, top US health officials have said. In the meantime, treatments are needed for those who have COVID-19, the disease caused by the virus. Drug companies including Gilead Sciences have been looking to repurpose drugs in that effort. Visit Business Insider's homepage for more stories . Drugmakers are racing to find treatments and vaccines to counter the coronavirus pandemic. The companies — including giants like Johnson & Johnson, Sanofi, Merck, and Gilead Sciences — are taking a variety of approaches. Some are hunting for near-term treatment options, either by testing existing drugs or investigating new antivirals or antibodies.
   Microsoft : Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing | MarketScreener  2020/05/18 16:41:04 MarketScreener
LabCorp, through its Covance drug development business, will provide a safe, in-person COVID-19 sample collection service from the convenience of patients' homes … | May 18, 2020

 関連キーワード  (― 米国株 アデプタス・ヘルス ADPT )

 twitter  (公式ツイッターやCEOツイッターなど)